FY2024 EPS Estimates for agilon health Decreased by Analyst

agilon health, inc. (NYSE:AGL) – Equities research analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for shares of agilon health in a report released on Monday, November 11th. Leerink Partnrs analyst W. Mayo now anticipates that the company will earn ($0.65) per share for the year, down from their prior forecast of ($0.35). The consensus estimate for agilon health’s current full-year earnings is ($0.43) per share. Leerink Partnrs also issued estimates for agilon health’s Q4 2024 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.39) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at ($0.18) EPS and FY2028 earnings at ($0.07) EPS.

AGL has been the subject of several other reports. Deutsche Bank Aktiengesellschaft reduced their target price on agilon health from $5.00 to $4.00 and set a “hold” rating for the company in a report on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price on shares of agilon health in a research report on Wednesday, August 7th. JMP Securities lowered agilon health from an “outperform” rating to a “market perform” rating in a research report on Monday, November 11th. Benchmark reissued a “buy” rating and set a $9.00 price objective on shares of agilon health in a report on Thursday, August 8th. Finally, Barclays lowered their price objective on agilon health from $5.00 to $2.00 and set an “underweight” rating on the stock in a report on Monday, November 11th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, agilon health presently has a consensus rating of “Hold” and an average target price of $6.38.

agilon health Trading Down 7.3 %

NYSE:AGL opened at $1.59 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.29 and a current ratio of 1.29. The stock has a market cap of $653.05 million, a price-to-earnings ratio of -1.69 and a beta of 0.60. The business has a fifty day moving average of $3.05 and a 200-day moving average of $4.86. agilon health has a 1 year low of $1.58 and a 1 year high of $13.76.

agilon health (NYSE:AGL) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.19). agilon health had a negative return on equity of 47.84% and a negative net margin of 6.88%. The business had revenue of $1.45 billion during the quarter, compared to the consensus estimate of $1.47 billion. During the same period in the previous year, the company posted ($0.06) EPS.

Insiders Place Their Bets

In related news, CEO Steven Sell purchased 20,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average cost of $3.36 per share, for a total transaction of $67,200.00. Following the completion of the purchase, the chief executive officer now owns 67,590 shares in the company, valued at approximately $227,102.40. This represents a 42.03 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On agilon health

Several institutional investors have recently made changes to their positions in the stock. Barclays PLC boosted its stake in shares of agilon health by 21.2% in the third quarter. Barclays PLC now owns 1,228,952 shares of the company’s stock valued at $4,830,000 after buying an additional 214,830 shares during the period. XTX Topco Ltd boosted its stake in shares of agilon health by 271.1% in the third quarter. XTX Topco Ltd now owns 119,747 shares of the company’s stock valued at $471,000 after buying an additional 87,481 shares during the period. State Street Corp boosted its stake in shares of agilon health by 3.0% in the third quarter. State Street Corp now owns 7,449,706 shares of the company’s stock valued at $29,277,000 after buying an additional 215,733 shares during the period. Quadrature Capital Ltd bought a new stake in shares of agilon health in the third quarter valued at approximately $261,000. Finally, Point72 DIFC Ltd bought a new stake in shares of agilon health in the third quarter valued at approximately $99,000.

About agilon health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.